Furthermore, GFRA1 is more prevalent and highly expressed in tumors that have become refractory to chemotherapeutics [14], and expression of this signaling pathway can facilitate resistance to aromatase inhibitors used in breast cancer therapy [17, 18]. Here, GFRA1 is linked to breast carcinoma.